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Abstract
B-cell depletive therapies have beneficial effects in patients
suffering from rheumatoid arthritis. Nevertheless, the role of B
cells in the pathogenesis of the disease is not clear. In particular,
it is not known how the regeneration of the B-cell repertoire
takes place. Two patients with active rheumatoid arthritis were
treated with rituximab, and the rearranged immunoglobulin
heavy-chain genes (Ig-VH) were analysed to follow the B-cell
regeneration. Patient A was treated with two courses of
rituximab, and B-cell regeneration was followed over 27 months
by analysing more than 680 Ig-VH sequences. Peripheral B-cell
depletion lasted 7 months and 10 months, respectively, and
each time was accompanied by a clinical improvement. Patient
B received one treatment course. B-cell depletion lasted 5
months and was accompanied by a good clinical response. B
cells regenerated well in both patients, and the repopulated B-
cell repertoire was characterised by a polyclonal and diverse
use of Ig-VH genes, as expected in adult individuals. During the
early phase of B-cell regeneration we observed the expansion
and recirculation of a highly mutated B-cell population. These
cells expressed very different Ig-VH genes. They were class-
switched and could be detected for a short period only. Patient
A was followed long term, whereby some characteristic
changes in the VH2 family as well as in specific mini-genes like
VH3–23, VH 4–34 or VH 1–69 were observed. In addition,
rituximab therapy resulted in the loss of clonal B cells for the
whole period.
Our data show that therapeutic transient B-cell depletion by
anti-CD20 antibodies results in the regeneration of a diverse
and polyclonal heavy-chain repertoire. During the early phase of
B-cell regeneration, highly mutated B cells recirculate for a short
time period in both the patients analysed. The longitudinal
observation of a single patient up to 27 months shows subtle
intraindividual changes, which may indicate repertoire
modulation.
Introduction
Although the role of B cells in autoimmunity is not completely
understood, their importance in the pathogenesis of autoim-
mune diseases has been further appreciated in the past few
years. It is now well known that B cells are more than just the
precursors of (auto)antibody-secreting cells [1-4]. They are
also involved in the regulation of T-cell-mediated autoimmune
diseases by different mechanisms. In this regard, B cells are
very efficient antigen-presenting cells. Activated B cells
express co-stimulatory molecules, such as CD154, and in this
way contribute to the evolution of T effector cells. They can
produce chemokines and cytokines, like lymphotoxin α /β , that
are essential for the differentiation of follicular dendritic cells in
secondary lymphoid organs and for the organisation of effec-
tive lymphoid architecture.
There are also indications that B-cell activity is enhanced in
rheumatoid arthritis (RA) [2,5]. B cells are found in the syn-
ovium, where they form aggregates with T cells and develop
tertiary lymphoid tissue structures [5]. The mutational activity
of these B cells is markedly enhanced and abnormalities in
positive selection and negative selection are found [2].
bp = base pair; CDR = complementary determining region; CRP = C-reactive protein; DAS28 = disease activity score; Ig-VH = immunoglobulin heavy-
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Furthermore, elimination of B cells by anti-CD20 antibodies
from the synovial tissue provokes a disruption of T-cell activa-
tion and provokes the production of proinflammatory monok-
ines [6], proving an important role of B cells in the
pathogenesis of RA.
The B-cell repertoire is shaped by a complex set of gene rear-
rangements, somatic hypermutation and receptor-driven
selection. These processes are highly regulated during devel-
opment, ontogeny and the response to antigen [7]. B cells
develop in the bone marrow and in the foetal liver, and they
mature in the peripheral lymphoid organs. The immunoglobu-
lins they produce contain two heavy polypeptide chains and
two light polypeptide chains. The different gene segments are
assembled together during recombination to produce a
unique rearrangement. The diversity of the repertoire is
increased by the addition of or the deletion of nucleotides at
the junction between the different gene segments and by ran-
dom pairing of the heavy chains and light chains. Additional
diversity is created by somatic hypermutation, which intro-
duces point mutations to change amino acid codons. This final
event takes place in germinal centres, when B cells encounter
antigen. The composition of the antibody repertoire is regu-
lated and constrained, and there is substantial evidence that
the B-cell repertoire is changed in autoimmune diseases, such
as systemic lupus erythematosus [1], Sjögren's syndrome
[8,9], myasthenia gravis [10], diabetes mellitus [11,12] or RA
[13,14].
B-cell depletive therapies have beneficial effects in patients
suffering from RA [14-22]. Rituximab is a chimeric anti-CD20
monoclonal antibody that consists of human IgG1 and kappa
constant regions and of mouse variable regions from a hybrid-
oma directed at human CD20. Rituximab has mainly been
used for the treatment of non-Hodgkin lymphomas [23]. It
selectively depletes CD20+ B cells from the peripheral blood,
the spleen and the bone marrow for several months [18].
Because early B-cell precursors do not express CD20, the
bone marrow is able to repopulate B lymphocytes after
therapy.
The aim of the present study was to determine whether a pol-
yclonal and diverse B-cell repertoire is regenerated after tem-
porary B-cell depletion by anti-CD20 monoclonal antibodies.
To address this issue, we have analysed the immunoglobulin
heavy-chain gene (Ig-VH) repertoire of two patients suffering
from active RA before and after treatment with rituximab, up to
a time period of 27 months.
Materials and methods
Patients
A 46-year-old male patient (patient A) was diagnosed with RA
using the American College of Rheumatology criteria. The
patient was unsuccessfully treated over a time period of 8
years with three disease-modifying anti-rheumatic drug regi-
mens including methotrexate, and also failed therapy with
tumour necrosis factor alpha blockers. After giving informed
consent, the patient was treated in an open-label protocol,
which was approved by the local ethics committee.
Rituximab (Mabthera®; Hoffmann La-Roche, Grenzach-
Whylen, Germany) was administered intravenously at a dose
of 375 mg/m2 once a week for a total of four infusions (days 1,
8, 15 and 22). The disease eventually relapsed 15 months
after the beginning of the study. The patient therefore received
another rituximab treatment (four once-weekly doses of 375
mg/m2) at the time point of 17 months. Except for 5 mg pred-
nisolone equivalent daily, the patient received no other antipro-
liferative treatment during the whole study.
Patient B was a 63-year-old female patient with rheumatoid
factor (RF)-positive RA. She had been unsuccessfully treated
over a time period of 7 years with three different disease-mod-
ifying anti-rheumatic drug regimens including methotrexate.
The patient has not yet been treated with a tumour necrosis
factor alpha blocking therapy. After informed consent, she was
treated with rituximab according to the same protocol as
patient A. In addition, patient B continued to receive 20 mg
methotrexate weekly. She did not receive any glucocorticoids
during the study.
The analysis of lymphocyte subsets by immunofluorescence
staining was performed by incubating peripheral blood mono-
nuclear cells (PBMCs) with anti-CD19 and anti-CD3 antibod-
ies (Phycoerythrin (PE) or Fluorescein isothiocyanate (FITC)-
labelled as indicated; all antibodies from Becton-Dickinson,
Heidelberg, Germany) using a FACSCalibur (Becton-Dickin-
son, San Jose, CA, USA). Frequencies of cell populations
were calculated using CellQuest software.
Disease activity was regularly determined using the disease
activity score (DAS28 index) and by monitoring C-reactive
protein (CRP) levels.
Amplification of rearranged immunoglobulin V genes by 
PCR
Genomic DNA was isolated from PBMCs using the QIAamp®
DNA Blood Mini Kit (Qiagen, Hilden, Germany). Rearranged
VHDJH gene rearrangements were amplified for all VH families
using a nested PCR approach [24]. Genomic DNA was ampli-
fied in separate reactions for the six VH families (VH1 oligonu-
cleotide primers also co-amplify perfectly VH7 gene
rearrangements). The final concentrations of the reagents
were 200 µM each dNTP (Peqlab, Erlangen, Germany), 0.625
µM each primer, 2.5 mM MgCl2, 10 × PCR buffer II and 2.5 U
AmpliTaq DNA polymerase (Applied Biosystems, Foster City,
CA, USA).
During the external amplification round, 250 ng (5 µl) DNA
were amplified in a 75 µl reaction containing primers specificAvailable online http://arthritis-research.com/content/7/4/R714
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for the leader peptide sequence and a mixture of external JH
primers in a Gene Amp PCR System 2400 (Perkin Elmer,
Applied Biosystems, Foster City, CA, USA). The internal ampli-
fication round was conducted with the 5' primer specific for
framework region FR1 and a mixture of internal JH primers
using 5 µl of the product of the first amplification reaction as
template. The cycling parameters have been described previ-
ously [24]. Briefly, the annealing temperatures were 50°C for
the external amplification round and 65°C for the internal
round.
The polymerase error rate for the amplification of VH genes
using nested PCR has been documented to be 1 × 10-4 muta-
tions/bp [25].
RT-PCR
Total cellular RNA was extracted from 1 × 107 PBMCs after
lysis of the cells in 1.5 ml TRIZOL reagent (Gibco, Karlsruhe,
Germany) following the manufacturer's instructions.
The RT-PCR reaction was performed using Titan One Tube
RT-PCR system (Roche, Mannheim, Germany). First-strand
cDNA was synthesised at 42°C for 60 min in a 50 µl reaction
mix containing 5 mM dithiothreitol, 400 ng oligo-dT15, 200 µM
dNTP, 8 U RNAse inhibitor, 5 × RT-PCR buffer, 20 U high-
fidelity enzyme mix RT-AMV and 1 µg RNA. VH mRNA tran-
scripts were amplified by the nested PCR protocol described
earlier using 5 µl cDNA and C-region primers (Cµ, TCA GGA
CTG ATG GGA AGC CC; Cγ , CGA GCC GCT GGT CAG
AGC G; Cα , ACC CTC AGC GGG AAG ACC TT) as the 3'
primers in the first round.
Cloning of rearranged immunoglobulin V genes
All PCR products were separated by electrophoresis through
1.5% agarose and were visualised with ethidium bromide.
Successful amplifications were identified as a band corre-
sponding to a product of approximately 350 bp. The bands
were excised and subsequently purified using the MinElute
Gel extraction kit (Qiagen). The purified PCR products were
polished using the PCR polishing kit (Stratagene, Amsterdam
Zuidoost, The Netherlands), were ligated with Zero Blunt
pCR-blunt vector and were transformed into One Shot®
TOP10 cells (Invitrogen, Karlsruhe, Germany)
Sequencing and analysis of rearranged V genes
Plasmid DNA from clones containing gene inserts was pre-
pared using the Wizard Plus SV Minipreps DNA Purification
System kit (Promega, Mannheim, Germany). The DNA
sequences were determined using BigDye Terminator Cycle
Sequencing Ready Reaction kit (Perkin Elmer, Applied Biosys-
tems) and the M13 forward and reverse universal primers in an
automated genetic analyser ABI PRISM 310 (Applied Biosys-
tems). Germline immunoglobulin V genes were identified by
blast searching the VBase Sequence Directory [26].
Single cell sorting and PCR amplification
The procedure for single cell sorting and subsequent PCR
amplifications has been described previously [24]. Briefly, sin-
gle CD19+CD27- and CD19+CD27+ cells were sorted into
wells of 96-well plates using a FACStar Plus flow cytometer
with an automated single cell deposit unit (Beckton-Dickinson,
USA). After primer extension pre-amplification, the rearranged
VHDJH genes were amplified by nested PCRs using the same
oligonucleotides as those already described. After gel purifica-
tion (Qiagen), the PCR products were directly sequenced
Figure 1
Clinical response of rheumatoid arthritis (RA) patient A Clinical response of rheumatoid arthritis (RA) patient A. The disease activity score (DAS28 index) and C-reactive protein (CRP) (mg/dl) levels of the 
RA patient. The patient was treated twice with rituximab (at 0 months and 17 months). Arrows indicate the percentage of B cells detected in periph-
eral blood for the four time points analysed (0, 7, 17 and 27 months)Arthritis Research & Therapy    Vol 7 No 4    Rouzière et al.
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using the BigDye Terminator Cycle Sequencing Ready Reac-
tion kit (Perkin Elmer, Applied Biosystems) and the 5' V primer
used for the internal amplification.
Statistical analysis
The statistical analyses were performed using GraphPad soft-
ware http://www.graphpad.com/. Sequences were analysed
by the Fisher's exact test to compare the differences in the dis-
tribution of particular gene segments. The average lengths of
CDR3 were studied by the unpaired t test. The chi-square test
was used to compare the mutational frequencies.
Results
Clinical data
Figure 1 shows the clinical response of RA patient A during
the two treatment periods with rituximab. B cells accounted for
10.1% of peripheral lymphocytes at the beginning of the
study. A rapid B-cell depletion occurred after each therapy,
and lasted up to 7 months and 10 months, respectively. The
time points of 7 months and 27 months were the first times
where B cells were detectable in peripheral blood, either by
flow cytometry or by PCR (data not shown). The B-cell fre-
quency was 3% of total lymphocytes at 7 months and was
2.4% of total lymphocytes at 27 months (Fig. 1). Patient A had
an active disease before therapy, as indicated by a high CRP
level and a high DAS28 clinical activity index. The disease
activity declined continuously after rituximab therapy. The
patient had a good clinical response starting from 3 months
and lasting over 1 year. We observed a deterioration of the
clinical parameters about 13 months after the first therapy. The
patient therefore received a second treatment with rituximab at
17 months. Again, patient A presented a clinical improvement
following B-cell depletion. The arrows in Fig. 1 indicate the
four time points when the B-cell repertoire was studied. Table
1 presents the RF values. The RF activity declined quite rapidly
after rituximab therapy and followed the inflammatory activity,
with increasing values in relapse and falling values after the
second treatment.
Patient B started with B cells at 11% of the peripheral blood
lymphocytes. B cells were not detectable during the 5 months
following the rituximab treatment. B cells represented 2.4% of
peripheral lymphocytes at the time point of 5 months, and rep-
resented 3.1% at 6 months. The patient experienced a good
clinical response. The DAS28 declined from 6.0 before
therapy to 3.3 at 5 months, and the CRP values declined from
1.9 mg/dl to 0.65 mg/dl, respectively.
Distribution of VH genes in patient A (Fig. 2)
Immunoglobulin VH  gene rearrangements from peripheral
blood B cells of patient A were analysed using nested PCR,
followed by subcloning and sequencing at the time points indi-
cated in Fig. 1. A total of 687 clones were analysed: 179
clones before treatment, 199 clones during the first phase of
B-cell regeneration (7 months after the first therapy), 149
clones after 17 months, and 160 clones after 27 months (at
the time of the second B-cell regeneration). Only the produc-
tive rearrangements were taken into consideration.
VH1 family
VH1–69 and VH1–18 were the most frequently used VH1 fam-
ily members before therapy, comprising 68% of the
sequences analysed in this family. Significant changes in the
VH1 distribution could be observed 7 months after therapy.
VH1–02 was increased and became the predominant gene
(36% versus 4%, P  = 0.0038), whereas VH1–69 was
decreased (12% versus 36%, P = 0.0594). The VH1 gene dis-
tribution 17 months after therapy was largely comparable with
that before treatment (i.e. VH1–18 and VH1–69 were the most
often used genes). Notably, VH1–03 was increased and was
then the third most frequent gene (18%). The distribution of
the VH1 genes after 27 months was quite stable with no sig-
nificant differences to the previous time point, except that
VH1–03 was no longer found.
VH2 family
The gene VH2–05 was slightly predominant in the VH2 family
before treatment. The distribution was completely shifted
toward the usage of VH2–05 7 months after therapy (96% ver-
sus 59%, P = 0.0041), which 10 months later shifted back to
the rearrangement frequency found before treatment. At the
time point of 27 months, during the second regeneration
phase, the frequencies of the VH2 genes were similar to those
observed during the regeneration phase following the first
treatment (7 months after therapy).
Table 1
Rheumatoid factor values at different time points following the first anti-CD20 antibody therapy
Rheumatoid factor values (U/ml)
0 monthsa 2 months 5 months 7 months 13 months 17 months 27 months
Patient A 682 295 196 148 186 284 80
Patient B 196 124 130
aMonths after first therapy.Available online http://arthritis-research.com/content/7/4/R714
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VH3 family
The VH3 family is the largest family, comprising 22 members.
Ten family members were found before treatment, two of them
accounting for 45% of all VH3 rearrangements (VH3–23, 29%;
VH3–30/3–30.5, 16%). The newly regenerated B cells used a
greater variety of genes 7 months after therapy (16 different
VH3 gene segments were observed). The overall distribution
was similar to the first time point, except for VH3–07, which
was then over-represented (15% versus 2%, P = 0.059). The
gene VH3–23 was significantly increased 17 months after
therapy when compared with the previous time point (37%
versus 17%, P  = 0.0481), and was the most often repre-
sented gene, followed by VH3–09 (16% of all VH3 rearrange-
ments). No significant alterations in VH3 gene distribution
could be observed in the final time point, despite the tendency
for VH3–23 to decrease to its level found at the time point of
7 months.
VH4 family
One single gene in the VH4 family (VH4–34) was overex-
pressed before therapy, accounting for more than 40% of all
VH4 rearrangements. The therapy induced some significant
changes in the distribution of the VH4 genes. The frequency of
VH4–34 decreased (16% versus 41%, P = 0.0198), whereas
Figure 2
Immunoglobulin heavy-chain gene (Ig-VH) distribution in peripheral B cells from patient A at the different time points (0, 7, 17 and 27 months): (a)  VH1 genes, (b) VH2 genes, (c) VH3 genes, (d) VH4 genes and (e) VH5 genes Immunoglobulin heavy-chain gene (Ig-VH) distribution in peripheral B cells from patient A at the different time points (0, 7, 17 and 27 months): (a) 
VH1 genes, (b) VH2 genes, (c) VH3 genes, (d) VH4 genes and (e) VH5 genes. Results presented as the percentage of rearrangements expressing 
one particular gene within one VH family. * P < 0.05 using Fisher's exact test.Arthritis Research & Therapy    Vol 7 No 4    Rouzière et al.
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VH4–04 increased (21% versus 3%, P = 0.0302). VH4–59
was also increased and became the most frequently rear-
ranged gene (39% of the VH4 sequences after therapy). As
described for the VH3 family, there was also a greater variety
of genes used in the VH4 rearrangements after therapy. Seven
different gene segments were used before treatment, whereas
nine different gene segments were found after treatment. The
overall rearrangement frequency of the different genes at the
time point of 17 months was comparable with that observed
before therapy, except for certain genes like VH4–34 that
remained at the level seen directly after therapy. Significant
changes could be described between the points of 7 months
and 17 months after therapy. An increased frequency of the
genes VH4–39 and VH4–30.1/4–31 was observed (18% ver-
sus 3%, P  = 0.0443 and 24% versus 5%, P  = 0.0372,
respectively), as well as a decreased use of the genes VH4–
59 and VH4–04 (12% versus 39%, P = 0.0146 and 6% ver-
sus 21%, P = 0.0931, respectively). This distribution was then
quite stable up to 27 months.
VH5 family
Within the two-member VH5 family, VH5–51 was the predom-
inant gene at all four time points analysed. Its frequency signif-
icantly increased after the first therapy (86% versus 65%, P =
0.036), however, with a further tendency to fall to the pretreat-
ment level. In this family, two B-cell clones were found in the
repertoire before therapy (Fig. 3). The first clone comprised six
clonally related sequences, with the number of shared muta-
tions varying from zero to six per sequence. This first clone's
33-nucleotide CDR3 involved VH5–51 rearranged to D6-6
and JH5. The second clone consisted of seven clonally related
sequences (from which three were nonproductive since one
mutation in position 90 generated a stop codon). The CDR3
was 30 nucleotides long. It was composed by VH5-a
rearranged to D4–14 and JH4, and had between zero and four
mutations. Both B-cell clones disappeared after the first anti-
CD20 therapy; their rearrangements were no longer observed
and no other B-cell clones were detected during follow-up.
Use of D segments, distribution of JH gene segments and 
CDR3 length in patient A
All D gene families could be detected in the sequences ana-
lysed. Before treatment, the four-member D1 family was
under-represented compared with its representation in the
genome (3% versus 16% expected). On the contrary, the D6
family that comprises only three members was over-repre-
sented (31% versus 15%). A significant increase of the D1
family members was observed after therapy, bringing the fre-
quency to its expected level. Its usage decreased continuously
until 27 months. In parallel, D3 became the most frequently
used family starting from 17 months after therapy.
The analysis of the JH segments indicated that the overall dis-
tribution of these components did not vary with the treatment.
JH4 was represented most frequently (accounting for 50% or
more of all rearrangements), followed by JH6 (between 20%
and 30% of all rearrangements). The other genes were less
frequently used. A significant reduction of the JH6 use (20%
versus 30%, P = 0.0223), as well as a significant increase of
JH2 (7% versus 1%, P = 0.0069), was observed after the first
Figure 3
Genealogical trees of B-cell clones found before therapy in VH5 family in patient A Genealogical trees of B-cell clones found before therapy in VH5 family in patient A. The best matching germline VH gene segments are shown in 
ellipses. The letters in the circles refer to individual sequences. Upper circle, parental clones with the gene segments they are using. Dotted circles, 
deduced intermediates. The numbers alongside the arrows represent the number of mutations between the different sequences. Brackets, mutated 
codons; underlined, replacement mutations; italicised, mutation to stop codon.Available online http://arthritis-research.com/content/7/4/R714
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B-cell depletion. The rearrangement frequency of these two
gene segments returned to the pretreatment level at 17
months. No significant changes were observed in the other
families.
The CDR3 length was calculated by determining the number
of nucleotides from residues 95–102. The average length of
CDR3 before therapy was 38.0 nucleotides (± 11.0), ranging
from 9 to 75 nucleotides. After the first anti-CD20 treatment
(7 months after therapy) the average length was 36.9 nucle-
otides (± 9.4), ranging from 15 to 69 nucleotides; 17 months
after therapy the average length was 42.6 nucleotides (±
12.1), ranging from 15 to 78 nucleotides; and at the time point
of 27 months the average length was 42.3 nucleotides (±
10.7), ranging from 18 to 75 nucleotides.
Mutational frequencies in VH rearrangements in both 
patients (Fig. 4)
At the beginning of the study, the overall mutational frequency
in the VH genes of patient A was 1.4% (681 mutations/48,891
bp) (Fig. 4a). The mutational frequencies varied from nine
mutations/2,448 bp (0.4%) for the VH6 family to 278 muta-
tions/12,390 bp (2.2%) for the VH3 family. The majority of the
clones (113 out of 178) contained two mutations or less per
rearrangement (data not shown). During the first B-cell regen-
eration phase, the mutational frequencies varied from 383
mutations/6,940 bp (5.5%) for the VH2 family to 638 muta-
tions/6,542 bp (9.8%) for the VH1 family. The overall muta-
tional frequency was highly and significantly increased at this
time point (4,032 mutations/54,720 bp [7.4%] versus 681
mutations/48,891 bp [1.4%] before therapy, P < 0.0001).
Almost 90% of the sequences analysed (175 out of 198) had
Figure 4
Mutational frequencies in VH rearrangements in (a) patient A and (b) patient B Mutational frequencies in VH rearrangements in (a) patient A and (b) patient B. * P < 0.0001 using the chi-square test.Arthritis Research & Therapy    Vol 7 No 4    Rouzière et al.
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more than 10 mutations per sequence. The frequency of muta-
tions at the time point of 17 months was decreased again to
the level found before treatment (519 mutations/39,307 bp
[1.4%]) and 92 sequences out 145 contained two mutations
or less per rearrangement. The overall mutational frequency
stayed in the same low range at the later time points up to 27
months (725 mutations/44,037 bp [1.6%]). Only the distribu-
tion of the mutations per rearrangement was somewhat
distinct, since 24 out of 159 sequences (15.1%) contained
more than 10 mutations (versus 10.1% and 9.7%, before and
17 months after therapy, respectively).
The second patient (patient B) was analysed for mutational fre-
quencies in the Ig-VH repertoire. The results for the VH4 family
are presented in Fig. 4b. The mutational frequency before ther-
apy was 1.5% (110 mutations/7,148 bp). Only two
sequences out of 26 presented more than 10 mutations per
sequence. At the early regeneration point (5 months after ther-
apy), the frequency of mutations was significantly increased to
5.4% (394 mutations/7,292 bp, P < 0.0001) and the majority
of the sequences (15 out of 26) contained more than 10 muta-
tions. Four weeks later, the mutational frequency was
decreased to 2.8% (169 mutations/6,151 bp). The number of
sequences containing more than 10 mutations (five out of 23)
was lower than in the previous time point but was still elevated
compared with that before therapy.
Overall mutational frequencies of VH rearrangements 
from single CD19+ cells in patient A (Table 2)
In order to substantiate the unexpected high mutation rate
observed 7 months after the first B-cell depletion, PBMCs of
patient A were sorted into single CD19+ cells that were either
CD27+ or CD27-. This different approach also revealed very
high mutational frequencies in both B-cell populations. The
overall mutational frequencies of CD19+CD27- single cells
before therapy were as low as expected (0.6%). At the time
point 7 months, during the first regeneration phase, the muta-
tional frequency was significantly elevated in both CD27- B
cells (5.3%) and CD27+ B cells (8.3%).
Discussion
The implication of B cells in the pathogenesis of RA is now
well established, but their precise role is still unknown. Numer-
ous studies have shown that B-cell depletion by anti-CD20
therapy can be beneficial for patients suffering from RA
[15,16,19-22]. However, it is not known how the B-cell reper-
toire regenerates after anti-CD20-mediated transient B-cell
depletion. In particular, whether a polyclonal and diverse
repertoire is reconstituted has not been studied. To address
this question, we decided to compare the B-cell repertoire of
a RA patient before and after effective clinical B-cell depletive
therapy by analysing his Ig-VH repertoire over a time period of
27 months.
A patient with active RA was selected for B-cell depletion
using rituximab. He showed a good clinical response for over
1 year after antibody treatment. The disease eventually
relapsed and the patient was retreated with rituximab. The sec-
ond B-cell depletive therapy again induced a significant clini-
cal response lasting about 10 months.
At the beginning of the study, the Ig-VH repertoire of the RA
patient basically resembled the published distributions for
healthy people [24,27]. Nevertheless, certain genes already
described with bias in autoimmune diseases were used in a
different proportion. In particular, the genes VH1–69 and VH4–
34 were over-represented. The gene VH1–69, which repre-
sented 35.7% of the rearrangements for the VH1 family in the
present study, has been found at the frequency of 11.1% in
healthy persons [24]. The gene VH4–34 represented 41.2%
of the VH4 genes in our RA patient. Its frequency in healthy
people has been described as 14.3% [24] and 15.7% [27].
On the other hand, the gene VH3–07 was found in a smaller
proportion (2.2% of the VH3 genes versus 7.5% [24] and
10.8% [27] in healthy controls). These genes have been
shown to exhibit some evidence for (auto)antigen selection;
for example, for RF activity [8]. In particular, the gene VH4–34
is very often used by anti-DNA antibodies [28,29] and is exclu-
sively used by cold agglutinins [30]. In agreement with Huang
and colleagues' data [13], the gene VH3–30 was found less
frequently in our RA patient than in the controls. In addition to
these genes, the proportion of some other variable genes like
VH1–02, 1–18 or 4–04 also differed from the published data
of normal controls and provided a distinct pattern for this
patient.
Table 2
Comparison of the overall mutational frequencies of VH rearrangements obtained from individual peripheral CD19+ (CD27- or 
CD27+) B cells of rheumatoid arthritis patient A before therapy and 7 months after first therapy
Before therapy 7 months after therapy
n Mutations (n) Total bp Mutational frequency (%) n Mutations (n) Total bp Mutational frequency (%)
CD19+CD27- 18 27 4,349 0.62 15 183 3,443 5.31*
CD19+CD27+ Not determined 22 477 5,745 8.30
* P < 0.0001 versus before therapy using chi-square test.Available online http://arthritis-research.com/content/7/4/R714
R722
The analysis of D segments and JH genes showed distributions
comparable with those described in healthy individuals
[24,27,31]. D6 represented the predominant D family and JH4
was the most frequently used JH segment, followed by JH6. The
only difference we detected before therapy was the under-rep-
resentation of the D1 family. The CDR3 length average (38.0
± 11.0 nucleotides) was in agreement with published data
[32].
These observations suggest that the overall representation of
individual VH genes in peripheral B cells in the present RA
patient resembled the repertoire expected in an adult, but also
contained characteristic differences in certain genes already
seen to often be biased in autoimmune diseases.
B cells regenerated well after B-cell depletion, and showed a
diverse and polyclonal repertoire. Nevertheless, changes in
the Ig-VH genes were detected, with the most profound effects
observed 7 months after the beginning of therapy, during the
early regeneration phase. The intraindividual long-term
changes were more subtle.
Seven months after the first therapy was the earliest time point
when peripheral B cells could be detected either by flow
cytometry or by PCR. These early regenerated B cells pre-
sented a distribution of Ig-VH genes significantly different from
that before therapy. Some VH genes (such as VH1–02 or VH3–
07) were more often used, whereas other genes (e.g. VH4–34)
were decreased. Also, significant changes were observed in
the distribution of the D segments and JH genes. The most
striking differences were the mutational frequencies found in
the VH genes (Fig. 4a). At this time point, 3% of the peripheral
lymphocytes were CD19+ B cells. All the amplified sequences
were extensively mutated (mean mutation rate, 7.4%): 88%
contained more than 10 mutations per sequence. This was
highly significant when compared with the data observed
before therapy and at the time point of 17 months, where only
10% of the rearrangements comprised more than 10 muta-
tions per sequence. This increase of mutations correlated well
with the diminution of JH6 usage and the tendency of lower
CDR3 length, and argues the influence of antigen contact and
T-cell help [8,31].
The high mutation rates were unexpected. This result is not
likely to be related to selective amplification of specific
sequences by our PCR protocol, since the high mutation rates
were observed in all VH families amplified using different PCR
conditions. Furthermore the detected repertoire was
polyclonal, and even presented an extended number of VH
genes. We nevertheless wanted to substantiate this result
using a different approach. We therefore sorted single cells
from this time point in CD27+ and CD27- B-cell subpopula-
tions. The increase of mutational frequency was confirmed:
again, the newly recirculating B cells showed increased muta-
tion rates. This was detectable in both CD27+ and CD27- B
cells (8.3% for CD27+ and 5.3% for CD27- versus 0.6% for
the CD27- cells before therapy; Table 2). The fact that even the
CD27- B cells were highly mutated was surprising, since
CD27 is assumed to be a marker for memory B cells with
mutated immunoglobulin receptors [33,34]. Mutated CD27- B
cells have, however, been described in a study by Hansen and
colleagues in patients with Sjögren's syndrome [35]. Reparon-
Schuijt and colleagues also described, in the synovium of RA
patients, a population of B lymphocytes that were functionally
and phenotypically distinct from classic memory cells [36].
These cells were CD20+, CD38- and CD27-, and they pro-
duced immunoglobulins under induction but had a defective
proliferative responsiveness.
To determine the heavy chain class distribution, we performed
RT-PCR on total RNA from this time point (7 months), using
primers specific for IgM, IgG and IgA. The IgM population was
slightly mutated as expected (1.7%), but the IgG (9.0%) and
IgA (8.9%) populations were highly mutated, in the same
range as the genes amplified from genomic DNA (7.4%). This
is in line with the assumption that the regenerating B cells at
this time point were class-switched B cells.
To address the question of whether the circulation of highly
mutated B cells in the early regeneration phase may be related
to the anti-CD20 mediated B-cell depletion, a second patient
was studied. We analysed the mutational frequencies in 75
VH4 rearrangements before treatment and 5 months and 6
months later, when B cells were again detectable in the
periphery (Fig. 4b). The elevated mutation rate of expressed Ig-
VH genes during the early regeneration phase was confirmed.
Before B-cell depletion, similar to patient A, about 8% of the
Ig-VH sequences were highly mutated. B-cell depletion in the
periphery lasted 5 months in patient B. At the time point of 5
months, 2.4% of peripheral lymphocytes were CD19+ B cells
and 46% of the analysed Ig-VH  sequences were highly
mutated. As in patient A, the phenomenon seems to be tran-
sient since a decrease in the mutation rate was already
observed 4 weeks later in patient B. Only 22% of the rear-
rangements were highly mutated at this time point.
Although our findings are restricted to a small number of
patients, the observed changes in the B-cell repertoire are
highly probably related to the regeneration of B cells. We did
not observe other possible confounding factors. During this
phase, the patients had no change in their medication and did
not show any clinical signs of infection. Also, the CRP levels
did not change during this time period.
It is not known from which B-cell pool peripheral B cells regen-
erate after an anti-CD20-mediated B-cell depletion. A recent
paper using a mouse model for anti-CD20-mediated
immunotherapy demonstrates a hierarchy of B-cell sensitivities
using rituximab-mediated B-cell depletion [37]. Particularly,
germinal centre B cells and marginal zone B cells were moreArthritis Research & Therapy    Vol 7 No 4    Rouzière et al.
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resistant to depletion in vivo. The microenvironment, such as
resident macrophages, B-cell survival factors or circulatory
dynamics of B-cell subsets, influences their sensitivity to anti-
CD20-mediated depletion. It therefore seems probable that B-
cell regeneration arises from a distorted composition of the
mature B-cell compartment. The recirculating B cells during
the early regeneration phase seem not to be newly generated
cells, but are more probably resident cells that were resistant
to the antibody treatment. These cells form the first wave of
regenerating cells. Later B-cell repopulation is then taken over
by newly produced naive cells. Alternatively, B-cell regenera-
tion changes the local environment in the central immunologi-
cal organs in a way that plasma cells, which usually home in
the tissues or in bone marrow, recirculate in the periphery for
a short time period.
Except for the highly mutated population observed during the
early regeneration phase, the regenerated B-cell repertoire
was overall relatively stable. This is in agreement with the data
of Dijk-Hard and Lundkvist that followed the distribution of VH
gene families in five individuals over a time period of 9 years
[38]. A high degree of stability in the VHgene family repertoire
was described in that paper, except for one individual where a
changing pattern was observed that correlated with the pres-
ence of RF in serum at one time point.
Our study was not designed to detect specific disease-rele-
vant changes in the repertoire. However, in addition to the
treatment-induced reduction in disease activity, a specific
decline in RF activity was observed. The patient showed a high
RF activity before treatment. This activity decreased rapidly
after the first B-cell depletion and rose again in relapse at 17
months. The second rituximab treatment again resulted in a
significant fall of RF activity (Table 1). This rapid decrease in
RF is in line with a report in a larger series of patients treated
with rituximab [39]. The mechanism of a more selective effect
on autoantibody production is not clearly understood. Possi-
bly, RF-producing plasma cells are more dependent on the
new regeneration from the CD20+ B-cell pool. Since we do
not know precisely the Ig-VH genes used by RF-secreting B
cells, it is not possible to relate RF to the use of Ig-VH genes.
Nevertheless, there were distinct changes in the Ig-VH reper-
toire that paralleled the decrease in clinical activity – certain
genes were shown to fluctuate, for instance the genes of the
VH2 family or the gene VH3–23. The predominant gene of the
VH3 family, VH3–23, was found in a high proportion before
therapy, decreased 7 months after therapy, increased again
17 months after therapy, accompanied by a clinical relapse,
and decreased again 27 months after the first therapy. It is
also interesting to note that the use of JH6 segment in the VH3
rearrangements as well as the shorter CDR3s correlated with
the disease activity – when the disease was active, the JH6
segment was found in a higher proportion accompanied by a
shorter CDR3.
Regarding the VH4–34 gene already described to be fre-
quently used in autoimmune disorders, it was significantly
decreased with therapy and its frequency remained low after
therapy. Irrespective of the possible pathogenic role of these
changes, these results give evidence for a long-term modula-
tion of the VH gene repertoire induced by anti-CD20 antibody
treatment. Clonal expansion is a characteristic feature of the
patients with RA. B-cell clones have been found in peripheral
blood [13,14] and in synovial tissue [5,14]. In the present
study, we were able to detect two clones within the VH5 family
before therapy. The rearrangements used by these two clones
were no longer observed after therapy at all studied time
points up to 27 months. The inducible loss of clonal B cells is
also an indication for the modulation of the B-cell repertoire.
Even if their specificity is not known, the relevance of clonal B
cells in disease activity can be speculated.
Conclusion
The present study describes the Ig-VH repertoire development
after transient anti-CD20-mediated B-cell depletion. The
results show that therapeutic, even repeated, transient B-cell
depletions by anti-CD20 antibodies result in the regeneration
of a diverse and polyclonal heavy-chain repertoire. The early
phase of B-cell regeneration is characterised by the recircula-
tion of highly mutated B cells during a short time period in both
the patients analysed. The longitudinal observation of a single
patient up to 27 months indicates subtle intraindividual
changes, which cautiously favour the hypothesis of a thera-
peutic B-cell repertoire modulation.
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